Edoxaban tosylate monohydrate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 314259

CAS#: 1229194-11-9 (tosylate hydrate)

Description: Edoxaban is a potent, selective factor Xa inhibitor, which has good oral bioavailability. Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It is being developed by Daiichi Sankyo. It was approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.

Chemical Structure

Edoxaban tosylate monohydrate
CAS# 1229194-11-9 (tosylate hydrate)

Theoretical Analysis

MedKoo Cat#: 314259
Name: Edoxaban tosylate monohydrate
CAS#: 1229194-11-9 (tosylate hydrate)
Chemical Formula: C31H40ClN7O8S2
Exact Mass:
Molecular Weight: 738.272
Elemental Analysis: C, 50.43; H, 5.46; Cl, 4.80; N, 13.28; O, 17.34; S, 8.69

Price and Availability

Size Price Availability Quantity
100.0mg USD 150.0 Same day
200.0mg USD 250.0 Same day
500.0mg USD 450.0 Same day
1.0g USD 750.0 Same day
2.0g USD 1250.0 Same day
5.0g USD 1950.0 Same day
10.0g USD 2950.0 Same day
20.0g USD 3950.0 Same day
100.0g USD 8950.0 2 weeks
Click to view more sizes and prices
Bulk inquiry

Related CAS #: 1229194-11-9 (tosylate hydrate)   480449-71-6 (tosylate)   480448-29-1 (HCl)   480449-70-5 (free base)    

Synonym: DU-176; DU 176; DU176; DU176b; DU-176b; DU 176b; Edoxaban; Edoxaban tosylate monohydrate, trade name Lixiana; Savaysa;

IUPAC/Chemical Name: N1-(5-chloropyridin-2-yl)-N2-((1S,2R,4S)-4-(dimethylcarbamoyl)-2-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)cyclohexyl)oxalamide 4-methylbenzenesulfonate hydrate


InChi Code: InChI=1S/C24H30ClN7O4S.C7H8O3S.H2O/c1-31(2)24(36)13-4-6-15(27-20(33)21(34)30-19-7-5-14(25)11-26-19)17(10-13)28-22(35)23-29-16-8-9-32(3)12-18(16)37-23;1-6-2-4-7(5-3-6)11(8,9)10;/h5,7,11,13,15,17H,4,6,8-10,12H2,1-3H3,(H,27,33)(H,28,35)(H,26,30,34);2-5H,1H3,(H,8,9,10);1H2/t13-,15-,17+;;/m0../s1

SMILES Code: O=C(NC1=NC=C(Cl)C=C1)C(N[C@@H]2[C@H](NC(C(S3)=NC4=C3CN(C)CC4)=O)C[C@@H](C(N(C)C)=O)CC2)=O.CC5=CC=C(S(=O)(O)=O)C=C5.[H]O[H]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO.

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 738.272 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK548805/ PubMed PMID: 31644112.

2: Cervantes CE, Merino JL, Barrios V. Edoxaban for the prevention of stroke in patients with atrial fibrillation. Expert Rev Cardiovasc Ther. 2019 Apr;17(4):319-330. doi: 10.1080/14779072.2019.1598263. Epub 2019 Mar 27. Review. PubMed PMID: 30897988.

3: Pharmacoeconomic Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535088/ PubMed PMID: 30540394.

4: CADTH Canadian Drug Expert Committee Final Recommendation: Edoxaban: (Lixiana — Servier Canada Inc.): Indication: Venous Thromboembolic Events [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May. No abstract available. Available from http://www.ncbi.nlm.nih.gov/books/NBK534995/ PubMed PMID: 30540393.

5: Clinical Review Report: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Jun. Available from http://www.ncbi.nlm.nih.gov/books/NBK535077/ PubMed PMID: 30540391.

6: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Available from http://www.ncbi.nlm.nih.gov/books/NBK500740/ PubMed PMID: 29999799.

7: Linkins LA MD, MSc, FRCPC. Edoxaban is non-inferior to low-molecular-weight heparin for treating cancer-associated venous thromboembolism. BMJ Evid Based Med. 2018 Dec;23(6):230. doi: 10.1136/bmjebm-2018-111007. Epub 2018 Jun 29. Review. PubMed PMID: 29959155.

8: Edoxaban (Lixiana) [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Apr. Available from http://www.ncbi.nlm.nih.gov/books/NBK475920/ PubMed PMID: 29341555.

9: Institute for Quality and Efficiency in Health Care. Edoxaban -- Benefit Assessment According to §35a Social Code Book V [Internet]. Cologne, Germany: Institute for Quality and Efficiency in Health Care (IQWiG); 2015 Oct 28. Available from http://www.ncbi.nlm.nih.gov/books/NBK458399/ PubMed PMID: 29144699.

10: Hammwöhner M, Goette A. The safety of edoxaban for treating atrial fibrillation. Expert Opin Drug Saf. 2017 Nov;16(11):1295-1303. doi: 10.1080/14740338.2017.1372418. Epub 2017 Sep 18. Review. PubMed PMID: 28862063.

11: O'connor CT, Kiernan TJ, Yan BP. The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban). Expert Opin Drug Metab Toxicol. 2017 Jul;13(7):725-739. doi: 10.1080/17425255.2017.1338274. Epub 2017 Jun 13. Review. PubMed PMID: 28571507.

12: Gibson CM, Finks SW. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape? Am J Med. 2017 Aug;130(8):900-906. doi: 10.1016/j.amjmed.2017.02.048. Epub 2017 Apr 6. Review. PubMed PMID: 28390791.

13: Scheen AJ, Lancellotti P. [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease]. Rev Med Liege. 2016 Nov;71(11):517-524. Review. French. PubMed PMID: 28387109.

14: Weiss TW, Rohla M, Dieplinger B, Domanovits H, Fries D, Vosko MR, Gary T, Ay C. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper]. Wien Med Wochenschr. 2018 Apr;168(5-6):133-143. doi: 10.1007/s10354-017-0548-4. Epub 2017 Feb 24. Review. German. PubMed PMID: 28236004.

15: Curto A, Curto D, Sanchez J. Managing patients taking edoxaban in dentistry. J Clin Exp Dent. 2017 Feb 1;9(2):e308-e311. doi: 10.4317/jced.53431. eCollection 2017 Feb. Review. PubMed PMID: 28210454; PubMed Central PMCID: PMC5303336.

16: De Caterina R, Ageno W, Boriani G, Colonna P, Ghirarduzzi A, Patti G, Rossini R, Rubboli A, Schinco P, Agnelli G. Edoxaban in Atrial Fibrillation and Venous Thromboembolism-Ten Key Questions and Answers: A Practical Guide. Adv Ther. 2017 Mar;34(3):620-637. doi: 10.1007/s12325-017-0488-9. Epub 2017 Feb 13. Review. PubMed PMID: 28194578; PubMed Central PMCID: PMC5350200.

17: Poulakos M, Walker JN, Baig U, David T. Edoxaban: A direct oral anticoagulant. Am J Health Syst Pharm. 2017 Feb 1;74(3):117-129. doi: 10.2146/ajhp150821. Review. PubMed PMID: 28122753.

18: Aspromonte N, Colivicchi F. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure. Expert Opin Drug Metab Toxicol. 2017 Jan;13(1):113-122. Epub 2016 Nov 18. Review. PubMed PMID: 27819149.

19: Minguet J, Sims HM, Smith KH, Bramlage P. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. Expert Rev Clin Pharmacol. 2017 Jan;10(1):5-15. doi: 10.1080/17512433.2016.1258301. Epub 2016 Nov 17. Review. Erratum in: Expert Rev Clin Pharmacol. 2017 Jan;10 (1):1. PubMed PMID: 27817212.

20: AlHajri L, Jabbari S, AlEmad H, AlMahri K, AlMahri M, AlKitbi N. The Efficacy and Safety of Edoxaban for VTE Prophylaxis Post-Orthopedic Surgery: A Systematic Review. J Cardiovasc Pharmacol Ther. 2017 May;22(3):230-238. doi: 10.1177/1074248416675732. Epub 2016 Nov 2. Review. PubMed PMID: 27811198.

Additional Information

Related CAS#
1229194-11-9 (Edoxaban tosylate hydrate);
480449-70-5 (Edoxaban free base).